Optinose US Inc.

13 clinical trials · Sponsor

Record	Firm	Date
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (NCT06850805)	Optinose US Inc.	2025-07-28
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19 (NCT05035576)	Optinose US Inc.	2021-09-01
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps (NCT03960580)	Optinose US Inc.	2019-06-06
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps (NCT03747458)	Optinose US Inc.	2018-12-31
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps (NCT03781804)	Optinose US Inc.	2018-11-27
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video (NCT03591068)	Optinose US Inc.	2018-06-07

Every clearance here is in the API, with alerts when new ones post.